Search
forLearn
5 / 801 resultslearn cholecalciferol
learn PENTAVITIN®
learn riboflavin
learn procapil
Research
5 / 97 resultsresearch Glycoconjugate expression of cells of human anagen hair follicles during keratinization
Human anagen hair follicles have unique carbohydrate patterns during keratinization.
research Low‐dose oral minoxidil as treatment for non‐scarring alopecia: a systematic review
Low-dose oral minoxidil effectively treats non-scarring hair loss with some side effects like hypertrichosis and postural hypotension.
research In Vitro Suppression of Human Lymphocyte Activity by Minoxidil
Minoxidil may help hair growth by stopping immune system attacks on hair follicles.
research Twenty nail onychomadesis: An unusual finding in Cronkhite–Canada syndrome
A man with Cronkhite-Canada syndrome had all 20 nails detach but improved with treatment.
research Historical and Current Adenosine Receptor Agonists in Preclinical and Clinical Development
The document concludes that adenosine receptor agonists have potential for treating various conditions, but only a few are approved due to challenges like side effects and the need for selective activation.
Community Join
5 / 1000+ resultscommunity Clascoterone (Winlevi) now approved in Canada
The conversation is about the approval of Clascoterone (Winlevi) in Canada for hair loss treatment. One user expressed skepticism about its effectiveness due to low concentration.
community How long are Pelage going to milk the phase 2a results of PP405?
PP405, a potential hair loss treatment, is facing delays in releasing Phase 2 results, causing frustration among users who compare it to past failed treatments. Despite skepticism, some remain hopeful about PP405's future, while others discuss alternative treatments like Clascoterone and its expected market release.
community Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.
community FDA approves Cassiopea's WINLEVI (CB-03-01, 1% formulation) for Acne
The conversation is about the FDA approval of WINLEVI for acne treatment and the anticipation of Breezula, a hair loss treatment using the same active ingredient, which may indicate a positive future for Breezula's release. There is disappointment that Breezula's results are not optimal, but it is seen as progress in hair loss treatment.
community Winlevi (clascoterone 1%) anyone trying it
Winlevi (clascoterone 1%) is being discussed as a potential hair loss treatment. Users are considering its use despite concerns about its delivery method.